SIN3A and pulmonary arterial hypertension: Intratracheal delivery of adeno-associated virus serotype 1 human SIN3a is a promising therapeutic approach in PAH by alleviating pulmonary vascular and right ventricular remodeling, decreasing right ventricular systolic pressure (RVSP) and mean pulmonary arterial pressure (mPAP), and reinstating BMPR2 expression (Fig. 3e).289 In summary, under SuHx-induced conditions, SIN3a exerts its influence on the progression of PAH by regulating epigenetic regulatory factors.